arrow
P

Paolo Andrea Zucali

IRCCS Humanitas Research Hospital
H指数:46
被引数:7,328

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study

转移性肾细胞癌一线治疗方案的选择模式:Meet-URO 33—REGAL研究的真实世界分析

2026-08-200
PRE
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: PSA persistence, biochemical recurrence, hormone-sensitive and castration-resistant metastatic settings

AIMN、AIOM、AIRO、SIU、SIUrO和Meet-URO联合调查关于PSMA PET成像在意大利前列腺癌中的应用:PSA持续存在、生化复发、激素敏感性和去势抵抗性转移性设置

2026-08-012
OA
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study

可解释机器学习预测转移性肾细胞癌免疫治疗结局——Meet-URO 15-AI研究

2026-07-020
OAAI
Novel PET tracers to distinguish the nature of residual masses after the completion of chemotherapy in metastatic testicular germ cell tumours: A systematic review

新型PET示踪剂以区分转移性睾丸生殖细胞肿瘤化疗后残留肿块的性质:一项系统综述

2026-07-020
OAAI
CHIMERA: a phase II study of neoadjuvant pembrolizumab in combination with cisplatin or carboplatin and pemetrexed followed by surgery and adjuvant pembrolizumab in resectable pleural mesothelioma

CHIMERA:一项关于新辅助培美曲塞联合顺铂或卡铂和培美曲塞,随后进行手术及辅助培美曲塞治疗可切除胸膜间皮瘤的II期研究

2026-05-270
OAAI
Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study

前列腺癌药物相互作用决策工具中大型语言模型的验证:与UpToDate的比较研究。Meet-URO 5/25 - GENIE研究

2026-05-150
PRE
Dynamic Evaluation Of The Glycolytic Determinants LDH-A And GLUT-1 Enhances Prognostic Significance And Their Inhibition Affect The Growth Of Mesothelioma Spheroids

动态评估糖酵解决定因子LDH-A和GLUT-1可增强其预后意义,且它们的抑制影响间皮瘤球体的生长

2026-03-230
OAAI
Malignant Pleural Mesothelioma (MPM) Evaluation with [11C]-Methionine PET/CT Before and After Talc Pleurodesis

Malignant Pleural Mesothelioma (MPM)在滑石粉胸膜固定术前后使用[11C]-蛋氨酸 PET/CT 进行评估

2026-03-090
PRE
Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions

Cecchi, L.G.; Aliprandi, M.; De Vincenzo, F.; Perrino, M.; Cordua, N.; Borea, F.; Bertocchi, A.; Federico, A.; Marulli, G.; Santoro, A.; 等. 胸膜间皮瘤的围手术期治疗:现状与未来方向. Cancers 2025, 17, 3199. [Google Scholar] [CrossRef]

Cancers
IF4.4
2026-03-030
OAAI
Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study
2026-02-030
OA
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide tyme database

诱导治疗后的治疗反应:来自意大利全国性tyme数据库的晚期胸腺肿瘤结果

2025-12-050
PRE
Joint survey by AIMN, AIOM, AIRO, SIU, SIUrO, and Meet-URO about the use of PSMA PET imaging in prostate cancer in Italy: technical aspects and primary staging setting

AIMN、AIOM、AIRO、SIU、SIUrO 和 Meet-URO 关于意大利前列腺癌中PSMA PET成像使用的联合调查:技术方面和初始分期设置

2025-12-010
OAAI
Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24)

卡博替尼在转移性肾细胞癌一线治疗中的真实世界应用:CabFRONT研究(Meet-URO 24)

2025-10-130
OAAI
EFFECTIVENESS OF BISPHOSPHONATES AND DENOSUMAB ON RISK OF VERTEBRAL FRACTURES IN PROSTATE CANCER PATIENTS UNDER ANDROGEN-DEPRIVATION THERAPIES: A REAL-WORLD PROSPECTIVE STUDY

双膦酸盐和地诺单抗对接受雄激素剥夺治疗的 prostate cancer 患者发生椎体骨折风险的有效性:一项真实世界前瞻性研究

2025-09-300
PRE
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma

基于纳武利尤单抗的免疫疗法在真实世界老年转移性肾细胞癌患者中的疗效及通过Meet-URO评分进行的预后分层

2025-08-120
PRE
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB

恶性胸膜瘤相关的炎症微环境通过GPNMB促进肿瘤进展

2025-04-181
OA